Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: Volumetric analysis of extent of resection in single-center experience

Journal of Neuro-Oncology

Volumn 102, Issue 1, 2011, Pages 105-113

  Díez Valle, Ricardo ^a   Tejada Solis, Sonia ^a   Idoate Gastearena, Miguel Angel ^a   García De Eulate, Reyes ^a   Domínguez Echávarri, Pablo ^a   Aristu Mendiroz, Javier ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

5 aminolevulinic; Glioblastoma; Gross total resection; Surgery; Volumetric MRI

Indexed keywords

AMINOLEVULINIC ACID;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FLUORESCENCE IMAGING; GLIOBLASTOMA; HISTOLOGY; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; IMMUNOHISTOCHEMISTRY; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROGRESSION FREE SURVIVAL; SAFETY; SURVIVAL RATE; TUMOR BIOPSY; TUMOR VOLUME;

ADULT; AGED; AMINOLEVULINIC ACID; BRAIN NEOPLASMS; FEMALE; FLUORESCENCE; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROSURGICAL PROCEDURES; PHOTOSENSITIZING AGENTS; PROGNOSIS; SURVIVAL RATE; TUMOR BURDEN;

EID: 79952193058     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0296-4     Document Type: Article

References (26)

1. Albert FK, Forsting M, Sartor K, Adams H, Kunze S (1994) Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 34:45-61 (Pubitemid 24015065)
2. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang F, McCutcheon I, Hassenbusch S, Holland E, Hess K, Michael C, Miller D, Sawaya R (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190-198. doi: 10.3171/jns.2001.95.2.0190 (Pubitemid 32799739)
3. Sanai N, Berger MS (2008) Glioma extent of resection and its impact on patient outcome. Neurosurgery 62:753-764. doi: 10.1227/01.neu.0000318159.21731. cf (discussion 264-6)
4. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC et al (2008) Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62:564-576. doi:10.1227/01.neu.0000317304.315 79.17 (discussion 564-76)
5. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ, for the ALA-glioma Study Group (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392-401. doi:10.1016/S1470-2045(06) 70665-9
6. Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ (2000) Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 93:1003-1013 (Pubitemid 32800611)
7. Stummer W, Stocker S, Wagner S, Stepp H, Fritsch C, Goetz C et al (1998) Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery 42:518-525 (discussion 525-6)
8. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466. doi: 10.1016/S1470-2045(09)70025-7
9. Keles GE, Anderson B, Berger MS (1999) The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol 52:371-379 (Pubitemid 29505267)
10. Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF (2005) MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 26:2466-2474
11. Ushio Y, Kochi M, Hamada J, Kai Y, Nakamura H (2005) Effect of surgical removal on survival and quality of life in patients with supratentorial glioblastoma. Neurol Med Chir (Tokyo) 45:454-460 (discussion 460-1)
12. McGirt MJ, Chaichana KL, Gathinji M, Attenello FJ, Than K, Olivi A et al (2009) Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg 110:156-162. doi:10.3171/2008.4. 17536
13. Nabavi A, Thurm H, Zountsas B, Pietsch T, Lanfermann H, Pichlmeier U et al (2009) Five-aminolevulinic acid for fluorescence-guided resection of recurrent malignant gliomas: a phase ii study. Neurosurgery 65:1070-1076. doi:10.1227/01.NEU.0000360128.03597.C7 (discussion 1076-7)
14. Pirotte BJ, Levivier M, Goldman S, Massager N, Wikler D, Dewitte O et al (2009) Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients. Neurosurgery 64: 471-481. doi:10.1227/01.NEU.0000338949.94496.85 (discussion 481)
15. Stockhammer F, Misch M, Horn P, Koch A, Fonyuy N, Plotkin M (2009) Association of F18-fluoro-ethyl-tyrosin uptake and 5-aminolevulinic acid-induced fluorescence in gliomas. Acta Neurochir (Wien) 151:1377-1383. doi:10.1007/s00701-009-0462-7
16. Giese A, Bjerkvig R, Berens ME, Westphal M (2003) Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21:1624-1636. doi:10.1200/JCO.2003.05.063 (Pubitemid 46594118)
17. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996. doi:10.1056/NEJMoa043330 (Pubitemid 40349501)
18. Feigl G, Ritz R, Moraes M, Klein J, Ramina K, Gharabaghi A et al (2009) Resection of malignant brain tumors in eloquent cortical areas: a new multimodal approach combining 5-aminolevulinic acid and intraoperative monitoring. J Neurosurg (in press)
19. Chang S, Parney I, McDermott M, Barker F, Schmidt M, Huang W et al (2003) Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the glioma outcome project. J Neurosurg 98:1175
20. Senft C, Seifert V, Hermann E, Franz K, Gasser T (2008) Usefulness of intraoperative ultra low-field magnetic resonance imaging in glioma surgery. Neurosurgery 63:257-267
21. Lenaburg H, Inkabi K, Vitaz T (2009) The use of intraoperative MRI for the treatment of glioblastoma multiforme. Technol Cancer Res Treat 8:159
22. Hatiboglu MA, Weinberg JS, Suki D, Rao G, Prabhu S, Shah K, Jackson E, Sawaya R (2009) Impact of intraoperative high-field magnetic resonance imaging guidance on glioma surgery: a prospective volumetric analysis. Neurosurgery 64(suppl. 6):1073-1081 (discussion 1081)
23. Kuroiwa T, Kajimoto Y, Ohta T (1998) Development of a fluorescein operative microscope for use during malignant glioma surgery: a technical note and preliminary report. Surg Neurol 50:41-48 (discussion 48-9)
24. Shinoda J, Yano H, Yoshimura S, Okumura A, Kaku Y, Iwama T et al (2003) Fluorescence-guided resection of glioblastoma multiforme by using high-dose fluorescein sodium. Technical note. J Neurosurg 99:597-603. doi:10.3171/jns. 2003.99.3.0597 (Pubitemid 37040427)
25. Koc K, Anik I, Cabuk B, Ceylan S (2008) Fluorescein sodiumguided surgery in glioblastoma multiforme: a prospective evaluation. Br J Neurosurg 22:99-103. doi:10.1080/02688690701765524 (Pubitemid 351161554)
26. Kremer P, Mahmoudreza F, Ding R, Pritsch M, Zoubaa S, Frei E (2009) Intraoperative fluorescence staining of malignant brain tumors using 5-aminofluorescein-labeled albumin. Neurosurgery 64:53-60. doi:10.1227/01.NEU. 0000335787.17029.67 (discussion 60-61)